Having trouble accessing articles? Reset your cache.

Patients, payers await pricing plans for bluebird's first approved gene therapy

bluebird gained the first European approval of Zynteglo, a β-thalassemia gene therapy Monday, but payers and patients will have to wait until the end of next week for the company to announce pricing and commercialization plans.

bluebird bio

Read the full 371 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE